Praxis Precision Medicines financials
$281.00−1.63%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $7.5M | $302.0K | $357.0K | $431.0K | $515.0K | $468.0K |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $7.5M | $302.0K | $357.0K | $431.0K | $515.0K | $468.0K |
| Gross margin | — | — | — | — | — | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$96.9M | -$105.9M | -$97.0M | -$78.4M | -$76.1M | -$74.7M | -$64.0M | -$56.8M | -$37.5M | -$41.9M | -$27.8M | -$25.5M |
| Net income | -$83.7M | -$92.6M | -$88.9M | -$73.9M | -$71.1M | -$69.3M | -$58.7M | -$51.9M | -$32.7M | -$39.6M | -$26.9M | -$24.6M |
| Net margin | — | — | — | — | — | — | −786.3% | −17188.7% | −9153.2% | −9177.0% | −5219.0% | −5263.2% |
| Diluted EPS | $-2.87 | $-3.20 | $-3.49 | $-3.36 | $-3.31 | $-3.29 | $-2.93 | $-2.75 | $-1.74 | $-2.84 | $-2.94 | $-2.72 |
| EBITDA | -$96.9M | -$105.8M | -$97.0M | -$78.3M | -$76.0M | -$74.7M | -$63.9M | -$56.7M | -$37.4M | -$41.8M | -$27.8M | -$25.4M |
| Operating cash flow | -$77.5M | -$86.2M | -$76.3M | -$65.1M | -$54.7M | -$53.0M | -$56.1M | -$27.5M | -$27.3M | -$20.9M | -$23.9M | -$23.2M |
| Free cash flow | -$77.8M | -$86.2M | -$76.3M | -$65.1M | -$54.7M | -$53.0M | -$56.1M | -$27.5M | -$27.3M | -$20.9M | -$23.9M | -$23.2M |
| Diluted shares | 29.1M | 28.9M | 25.5M | 22.0M | 21.5M | 21.1M | 20.0M | 18.9M | 18.8M | 13.9M | 9.1M | 9.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $474.8M | $536.3M | $357.3M | $149.5M | $157.4M | $165.6M |
| Short-term investments | $283.8M | $250.5M | $242.0M | $117.6M | $143.9M | $162.4M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $1.39B | $1.46B | $937.9M | $396.4M | $452.8M | $478.7M |
| Total liabilities | $49.1M | $50.2M | $59.8M | $52.9M | $48.6M | $39.5M |
| Shareholders' equity | $1.34B | $1.41B | $878.1M | $343.5M | $404.2M | $439.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology